MSN Laboratories Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: MSN Laboratories Private Limited Pharmaceutical Export Portfolio Dataset — 32 Products, $252.1M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

MSN Laboratories Private Limited — Pharmaceutical Exporter Profile (2026) | 32 Products, $252.1M Trade | TransData Nexus

MSN Laboratories Private Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $252.1M Total Trade · DGFT Verified

MSN Laboratories Private Limited is an Indian pharmaceutical exporter with a total trade value of $252.1M across 32 products in 15 therapeutic categories. Based on 8,837 verified export shipments from Indian Customs (DGFT) records, MSN Laboratories Private Limited is the #1 Indian exporter in 2 products including Pomalidomide. Top exports include Atorvastatin ($83.7M), Rosuvastatin ($58.9M), Ras ($22.3M).

MSN Laboratories Private Limited — Export Portfolio & Destination Treemap

MSN Laboratories Private Limited pharmaceutical export portfolio — 32 products across 15 therapeutic categories. Source: Indian Customs (DGFT).

Who is MSN Laboratories Private Limited? — Company Overview & Market Position

MSN Laboratories Private Limited, established on August 27, 2003, is a Hyderabad-based pharmaceutical company committed to providing affordable healthcare solutions. The company is registered under the Corporate Identification Number (CIN) U24239TG2003PTC041583. As of March 2026, MSN Laboratories has an authorized capital of ₹100 crore and a paid-up capital of ₹52 crore. The company employs over 15,000 professionals, reflecting its significant presence in the pharmaceutical industry. MSN Laboratories operates across multiple countries, including the USA, Indonesia, and the UAE, with a diverse product portfolio encompassing over 500 APIs and 400 formulations across 35 major therapeutic areas.

What Does MSN Laboratories Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Atorvastatin$83.7M 2Rosuvastatin$58.9M

Product Portfolio — Top 30 by Export Value

MSN Laboratories Private Limited exports 32 pharmaceutical products across 15 therapeutic categories. Market leader (#1 exporter) in 2 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Atorvastatin	Cardiovascular	$83.7M	3,224	7.7%	4
2	Rosuvastatin	Cardiovascular	$58.9M	1,632	12.7%	2
3	Ras	Ayurvedic & Herbal Products	$22.3M	512	7.3%	4
4	Oseltamivir	Antivirals	$12.3M	245	10.0%	3
5	Calcium	Vitamins & Supplements	$7.8M	156	0.9%	11
6	Losartan	Cardiovascular	$7.4M	410	2.5%	12
7	Capecitabine	Advanced Oncology	$7.4M	323	8.4%	3
8	Telmisartan	Cardiovascular	$7.1M	619	0.1%	8
9	Paclitaxel	Oncology	$6.9M	138	8.3%	2
10	Febuxostat	Lipid & Metabolism	$6.0M	342	12.3%	2
11	Bortezomib	Advanced Oncology	$3.6M	97	16.4%	3
12	Sitagliptin	Diabetes & Endocrine	$3.2M	78	4.3%	8
13	Montelukast	Respiratory	$3.2M	295	1.9%	10
14	Darunavir	Antiviral & HIV Medications	$3.2M	68	5.2%	5
15	Dasatinib	Advanced Oncology	$2.6M	52	15.9%	3
16	Voriconazole	Advanced Antifungals	$2.5M	100	7.9%	3
17	Moxifloxacin	Advanced Antibiotics	$2.3M	89	7.0%	2
18	Exemestane	Advanced Oncology	$1.7M	34	11.7%	4
19	Cabazitaxel	Advanced Oncology	$1.6M	37	17.0%	2
20	Vati	Ayurvedic & Herbal Products	$1.3M	45	4.8%	5
21	Apixaban	Cardiovascular	$1.1M	23	0.6%	10
22	Sunitinib	Advanced Oncology	$1.0M	42	1.6%	4
23	Pomalidomide	Advanced Oncology	$950.0K	19	21.5%	1
24	Carmustine	Advanced Oncology	$850.0K	17	3.8%	2
25	Dapagliflozin	Advanced Diabetes Medications	$825.0K	42	1.7%	11
26	Levofloxacin	Antibiotics	$743.1K	102	1.0%	14
27	Erlotinib	Advanced Oncology	$529.7K	32	19.8%	2
28	Posaconazole	Advanced Antifungals	$307.2K	8	0.3%	4
29	Acetylsalicylic	Combination Drugs	$263.2K	12	6.0%	5
30	Salicylic	Combination Drugs	$263.2K	12	1.6%	12

MSN Laboratories Private Limited exports 32 pharmaceutical products across 15 therapeutic categories with a total export value of $252.1M. The company is the #1 Indian exporter in 2 products: Pomalidomide. The top category is Cardiovascular (62.8% of portfolio), followed by Ayurvedic & Herbal Products (9.3%), indicating a concentrated portfolio with the top 5 products accounting for 73.4% of total export value.

Showing top 30 of 32 products. Contact us for complete data.

MSN Laboratories Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

MSN Laboratories operates 17 Active Pharmaceutical Ingredient (API) facilities and 8 finished dosage form (FDF) facilities across India, the USA, Indonesia, and the UAE. These facilities are equipped with state-of-the-art technology to ensure the production of high-quality pharmaceutical products. The company's manufacturing plants specialize in a wide range of therapeutic categories, including cardiovascular, oncology, and Ayurvedic & herbal products, catering to diverse global healthcare needs.

3Key Leadership

The leadership team at MSN Laboratories includes:

Satyanarayana Reddy Manne: Managing Director since August 27, 2003.

Bharat Reddy Chintapally: Director since February 1, 2007.

Laxmi Prasuna Manne: Director since August 27, 2003.

These leaders have been instrumental in steering the company towards its mission of delivering affordable healthcare solutions globally.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does MSN Laboratories Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

MSN Laboratories has established a strong presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals for its finished pharmaceutical formulations from various regulatory bodies, ensuring compliance with international standards. This regulatory compliance facilitates access to these markets, enabling MSN Laboratories to supply a wide range of pharmaceutical products to meet global healthcare demands.

2Emerging Markets

MSN Laboratories has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's products have been prequalified by the World Health Organization (WHO), which is a significant achievement that enhances its credibility and facilitates market access in these regions. This prequalification enables MSN Laboratories to supply essential medicines to countries with stringent regulatory requirements, thereby contributing to global health initiatives.

3Geographic Strategy

MSN Laboratories' geographic strategy demonstrates a balanced approach to market diversification. While the company has a strong presence in regulated markets, it has also made significant inroads into emerging markets, reducing concentration risk. This strategic diversification allows MSN Laboratories to mitigate potential market fluctuations and leverage growth opportunities across different regions.

MSN Laboratories Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

MSN Laboratories has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), ensuring compliance with U.S. regulatory standards. The company has filed multiple Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs), facilitating the approval of its generic pharmaceutical products in the U.S. market. FDA inspections have been conducted at various facilities, with the most recent Form 483 issued on June 25, 2024, indicating ongoing compliance efforts.

2WHO & EU GMP

MSN Laboratories has achieved prequalification from the World Health Organization (WHO), a testament to the quality and safety of its pharmaceutical products. The company has also obtained Good Manufacturing Practice (GMP) certifications from the European Union (EU), ensuring adherence to stringent manufacturing standards required for market access in EU member countries. These certifications underscore MSN Laboratories' commitment to maintaining high-quality manufacturing processes.

3CDSCO & Indian Regulatory

MSN Laboratories Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the cardiovascular therapeutic category, MSN Laboratories faces competition from other Indian pharmaceutical companies such as Aurobindo Pharma and Dr. Reddy's Laboratories. MSN Laboratories holds a 7.7% market share in atorvastatin and a 12.7% market share in rosuvastatin, indicating a strong position in this segment. In the antiviral segment, particularly for oseltamivir, MSN Laboratories competes with global pharmaceutical companies, holding a 10.0% market share. The company's diverse product portfolio across 15 therapeutic categories allows it to mitigate competitive pressures in any single market segment.

2Key Differentiators

MSN Laboratories' key differentiators include its extensive product portfolio, encompassing over 500 APIs and 400 formulations across 35 major therapeutic areas. The company's integrated research and development center for both APIs and formulations enables rapid product development and market entry. Additionally, MSN Laboratories' commitment to affordability and accessibility has earned it the trust of over 50 million patients across more than 100 countries.

3Strategic Position

Buyer Due Diligence Brief — Evaluating MSN Laboratories Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

MSN Laboratories has demonstrated a strong track record in pharmaceutical manufacturing, with a total export value of $252.1 million USD and 8,837 shipments across 32 products in 15 therapeutic categories. The company's top five products—atorvastatin, rosuvastatin, ras, oseltamivir, and calcium—account for 73.4% of its portfolio, indicating a focused approach to product development. The company's consistent growth and adherence to international quality standards make it a reliable supplier in the pharmaceutical industry.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Registration: Confirm the company's manufacturing facilities are registered with the U.S. Food and Drug Administration.

WHO Prequalification: Ensure the company's products are prequalified by the World Health Organization.

Frequently Asked Questions — MSN Laboratories Private Limited

How many pharmaceutical products does MSN Laboratories Private Limited export from India?

MSN Laboratories Private Limited exports 32 pharmaceutical products across 15 therapeutic categories. The top exports are Atorvastatin ($83.7M), Rosuvastatin ($58.9M), Ras ($22.3M), Oseltamivir ($12.3M), Calcium ($7.8M). Total export value is $252.1M.

What is MSN Laboratories Private Limited's total pharmaceutical export value?

MSN Laboratories Private Limited's total pharmaceutical export value is $252.1M, based on 8,837 verified shipments recorded in Indian Customs (DGFT) data.

In which products is MSN Laboratories Private Limited the #1 Indian exporter?

MSN Laboratories Private Limited is the #1 Indian exporter in 2 products: Pomalidomide (21.5% market share).

What therapeutic categories does MSN Laboratories Private Limited cover?

MSN Laboratories Private Limited exports across 15 therapeutic categories. The largest are Cardiovascular (62.8%, 5 products), Ayurvedic & Herbal Products (9.3%, 2 products), Advanced Oncology (8.1%, 11 products).

Get Full MSN Laboratories Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.